In a phase Ib trial (KEYNOTE-524), the mPFS and mOS of HCC patients treated with Lenvatinib and anti-PD-1 were 8.6 and 22 months, respectively (14). The gene discussed is PDCD1; the disease is hepatocellular carcinoma.